Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced histologically confirmed well differentiated pancreatic neuroendocrine tumor~* Progressive disease within the last 12 months~* Measurable disease per RECIST Version 1.0 determined by multiphase MRI or triphasic CT~Exclusion Criteria:~* Patients currently requiring somatostatin analog treatment~* Prior therapy with mTOR inhibitors or pasireotide~* Patients with more than 2 prior systemic treatment regimens~* Previous cytotoxic chemotherapy, targeted therapy, somatostatin analogs, or biotherapy within the last 4 weeks~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paseriotide LAR + Everolimus (Type: EXPERIMENTAL): everolimus 10 mg once daily po in combination with pasireotide LAR 60 mg every 28 days (q28d) im
- Everolimus (Type: EXPERIMENTAL): everolimus 10 mg once daily po alone

Based on this trial design, predict the completion outcome and termination type (if applicable).